First Quadrant’s Crescent Biopharma CBIO Stock Holding History

First Quadrant’s Portfolio CBIO Stock Details CBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-36	Closed	-$11K	–	551
2021 Q1	$11K	Sell	36 -19	-35%	-$6.8K	﹤0.01%	559
2020 Q4	$21K	Buy	+55	New	+$19.3K	﹤0.01%	516
2020 Q3	–	Sell	-264	Closed	-$99K	–	653
2020 Q2	$99K	Buy	+264	New	+$74.8K	0.01%	549
2019 Q1	–	Sell	-13	Closed	-$12K	–	747
2018 Q4	$12K	Hold	13	–	–	﹤0.01%	779
2018 Q3	$18K	Buy	+13	New	+$19.7K	﹤0.01%	815

Other funds holding CBIO

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

First Quadrant's CBIO Position: Q2 2021 in Review

First Quadrant sold out of Crescent Biopharma (CBIO) in Q2 2021, closing a stake of 36 shares — an estimated $11K sold.

First Quadrant first reported a position in CBIO in Q3 2018 and held it in 5 quarters. The position peaked at $99K in Q2 2020. 58 funds tracked by Wall St. Rank hold CBIO as of Q2 2021.

First Quadrant reported no remaining Crescent Biopharma position as of Q2 2021 after selling out during the quarter.
First Quadrant sold 36 Crescent Biopharma shares in Q2 2021, an estimated $11K.
First Quadrant first reported a position in Crescent Biopharma in Q3 2018 and held it in 5 quarters.
First Quadrant's Crescent Biopharma position peaked at $99K in Q2 2020.
58 funds tracked by Wall St. Rank held Crescent Biopharma as of Q2 2021.

Based on First Quadrant's 13F filing for Q2 2021, filed 23 Jul 2021.